GNOM - Graphite Bio: Selling For Much Less Than Net Cash

• Shares of Graphite Bio are down some 85% from their June 2021 IPO pricing, as its first-ever clinical trial for the treatment of sickle cell disease experienced a six-month delay.
• The company’s potentially curative technology builds on CRISPR Therapeutics by pasting a DNA template into the target gene after it has been cut.
• With no actionable data likely forthcoming until mid-2023 but trading at a significant discount to cash, the recent insider buying merited a deeper dive.
• A full investment analysis follows in the paragraphs below.

For further details see: